At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 510 enrolled
Drug / intervention
Tapinarof +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults
In Brief
A Phase 3 clinical trial evaluating Tapinarof and Vehicle Cream for Plaque Psoriasis. Completed, enrolled 510 participants across 53 sites in 2 countries.
Detailed Summary
This is a randomized, double-blind, vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesCanada, United States
CollaboratorsIQVIA Biotech
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartMay 2019
Primary CompletionMay 2020
TodayJul 2026
First PostedMay 20, 2019
Enrollment StartMay 21, 2019
Primary CompletionMay 26, 2020
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.1 years ago
Interventions
Tapinarofdrug
Tapinarof cream, 1%, applied once daily
Vehicle Creamdrug
Vehicle cream applied once daily